Influential professional organization recommends radiotherapy as the primary non-surgical alternative for patients with basal cell or cutaneous squamous cell carcinomas
BOCA RATON, Fla, July 14, 2020 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, and the leading provider of superficial radiotherapy (SRT), reports that new guidelines issued by the American Society for Radiation Oncology (ASTRO) recommends SRT as the first-line alternative to surgery when treating patients with non-melanoma skin cancer (NMSC). With more than 10,000 members, ASTRO is the world’s premier radiation oncology society and the authority on radiation therapy.
“Over the past five to seven years our management team has been working diligently alongside radiation oncologists to prove the efficacy of superficial radiotherapy. We want to thank ASTRO for providing clarity to the role of radiotherapy in treating NMSC, and these new guidelines will be valuable to Sensus’ sales and marketing efforts as they are clear, powerful and highly beneficial to SRT,” said Joe Sardano, Sensus Healthcare’s chief executive officer. “ASTRO is the leading authority on evidence-based medicine and treatment modalities involving radiation therapies, and their guidelines resonate strongly with physicians. We look forward to leveraging their view of radiotherapy as a first-line alternative to surgery with prospective SRT customers, and to encourage existing customers to increase their utilization of our SRT systems.”
“These guidelines by ASTRO coupled with the Consensus Report by the American Cutaneous Oncology Society, or ACOS, support our technology as the leading non-invasive treatment option for NMSC patients who are high-risk surgical candidates because of preexisting conditions, and for patients who simply want to avoid the pain, risk and aesthetic outcomes of surgery,” added Mr. Sardano. “The ASTRO guidelines are particularly timely during the COVID-19 pandemic in that the patient profile for skin cancer is aligned with the profile of those most at risk of severe illness or even death should they contract COVID-19. As such, they must be extra vigilant in minimizing exposure while treating their NMSC. During the COVID-19 outbreak, surgeries for skin cancer have been postponed for weeks or even months. However, physicians continued to use SRT devices while patient protocols were being finalized. SRT proved to be an excellent complement for Mohs surgeons, allowing them to treat patients during uncertain times. SRT has always been an efficacious treatment, yet with no risk of infection and rapid treatment times, it is even more attractive in today’s environment. You can trust our management team to continue the work we have been doing relentlessly to secure access for those patients with preexisting conditions so that they will have viable, safe, and affordable options that meets their needs.”
The new guidelines by ASTRO recommend definitive radiotherapy as a curative modality for patients with basal cell carcinoma or cutaneous squamous cell carcinoma who cannot undergo or who decline surgical resection. It was conditionally recommended as a curative treatment in situations where surgery risks have the potential to compromise function or trigger an adverse cosmetic result.
Sensus Healthcare’s line of SRT-100 devices utilizes Superficial Radiation Therapy (SRT) to treat non-melanoma skin cancers non-invasively and is an excellent option for keloid scarring. Superficial Radiation Therapy is 98% effective when used on non-melanoma skin cancer patients and is 94% effective for patients with keloid scarring.
The link to read the full ASTRO consensus guidelines can be found here.
The full press release can be found here.